Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment

Last updated: April 23, 2025
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cytomegalovirus Infections

Mental Disability

Dementia

Treatment

Non-Interventional Study

Clinical Study ID

NCT06870539
24-011332
P50CA136393
24-011332
NCI-2025-01230
  • Ages > 18
  • Female

Study Summary

This study evaluates the feasibility and accuracy of using saliva to remotely monitor cytomegalovirus (CMV) infection in individuals receiving treatment for ovarian cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18

  • Ability to read and write in English

  • Diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube)

  • Receiving care from providers at Mayo Clinic

  • Regardless of diseases status, actively receiving treatment for ovarian cancer (frontline, maintenance, progression, recurrence)

Exclusion

Exclusion Criteria:

  • Pregnant at the time of study participation

  • Inability to provide informed written consent

  • History of dementia, stroke, brain tumors or other condition which may impaircognitive functioning

Study Design

Total Participants: 28
Treatment Group(s): 1
Primary Treatment: Non-Interventional Study
Phase:
Study Start date:
March 07, 2025
Estimated Completion Date:
March 03, 2026

Connect with a study center

  • University of Minnesota/Masonic Cancer Center

    Minneapolis, Minnesota 55455
    United States

    Active - Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota 55905
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.